Aspalathin and Nothofagin from Rooibos (Aspalathus linearis) Inhibits High Glucose-Induced Inflammation In Vitro and In Vivo

Inflammation

Volumn 38, Issue 1, 2015, Pages 445-455

  Ku, Sae Kwang ^a   Kwak, Soyoung ^b   Kim, Yaesol ^b   Bae, Jong Sup ^b  

^a Daegu Haany University   (South Korea)

^b Kyungpook National University   (South Korea)

Author keywords

aspalathin; diabetes mellitus; high glucose; inflammation; nothofagin

Indexed keywords

ANTIINFLAMMATORY AGENT; ASPALATHIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NOTHOFAGIN; PLANT MEDICINAL PRODUCT; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; CHALCONE DERIVATIVE; GLUCOSE; PLANT EXTRACT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASPALATHUS LINEARIS; BLOOD VESSEL PERMEABILITY; CELL ADHESION; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; MALE; MONOCYTE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULITIS; WESTERN BLOTTING; ANIMAL; ASPALATHUS; C57BL MOUSE; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; INFLAMMATION; ISOLATION AND PURIFICATION; METABOLISM;

ANIMALS; ASPALATHUS; CELL SURVIVAL; CHALCONES; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; PLANT EXTRACTS;

EID: 84925489663     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-0049-1     Document Type: Article

References (51)

1. Whiting, D.R., L. Guariguata, C. Weil, and J. Shaw. 2011. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Research and Clinical Practice 94: 311–321.
2. Grundy, S.M., I.J. Benjamin, G.L. Burke, et al. 1999. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 100: 1134–1146.
3. Thomas, J.E., and J.M. Foody. 2007. The pathophysiology of cardiovascular disease in diabetes mellitus and the future of therapy. Journal of the Cardiometabolic Syndrome 2: 108–113.
4. Roglic, G., N. Unwin, P.H. Bennett, et al. 2005. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 28: 2130–2135.
5. Rubino, F., and M. Gagner. 2002. Potential of surgery for curing type 2 diabetes mellitus. Annals of Surgery 236: 554–559.
6. Day, C. 1998. Traditional plant treatments for diabetes mellitus: pharmaceutical foods. British Journal of Nutrition 80: 5–6.
7. Li, G.Q., A. Kam, K.H. Wong, et al. 2012. Herbal medicines for the management of diabetes. Advances in Experimental Medicine and Biology 771: 396–413.
8. Prior, R.L., and G. Cao. 1999. Antioxidant capacity and polyphenolic components of teas: implications for altering in vivo antioxidant status. Proceedings of the Society for Experimental Biology and Medicine 220: 255–261.
9. Warren, C.P. 1999. Antioxidant effects of herbs. Lancet 353: 676.
10. McKay, D.L., and J.B. Blumberg. 2007. A review of the bioactivity of South African herbal teas: rooibos (Aspalathus linearis) and honeybush (Cyclopia intermedia). Phytotherapy Research 21: 1–16.
11. Kazuno, S., M. Yanagida, N. Shindo, and K. Murayama. 2005. Mass spectrometric identification and quantification of glycosyl flavonoids, including dihydrochalcones with neutral loss scan mode. Analytical Biochemistry 347: 182–192.
12. Lee, W., S.K. Ku, and J.S. Bae. 2013. Emodin-6-O-beta-D-glucoside down-regulates endothelial protein C receptor shedding. Archives of Pharmacal Research 36: 1160–1165.
13. Bae, J.S., and A.R. Rezaie. 2013. Thrombin inhibits HMGB1-mediated proinflammatory signaling responses when endothelial protein C receptor is occupied by its natural ligand. BMB Reports 46: 544–549.
14. Kim, T.H., S.K. Ku, I.C. Lee, and J.S. Bae. 2012. Anti-inflammatory functions of purpurogallin in LPS-activated human endothelial cells. BMB Reports 45: 200–205.
15. Bae, J.S., W. Lee, and A.R. Rezaie. 2012. Polyphosphate elicits proinflammatory responses that are counteracted by activated protein C in both cellular and animal models. Journal of Thrombosis and Haemostasis 10: 1145–1151.
16. Lee, J.D., J.E. Huh, G. Jeon, et al. 2009. Flavonol-rich RVHxR from Rhus verniciflua Stokes and its major compound fisetin inhibits inflammation-related cytokines and angiogenic factor in rheumatoid arthritic fibroblast-like synovial cells and in vivo models. International Immunopharmacology 9: 268–276.
17. Bae, J.S., W. Lee, J.O. Nam, J.E. Kim, S.W. Kim, and I.S. Kim. 2014. Transforming growth factor beta-induced protein promotes severe vascular inflammatory responses. American Journal of Respiratory and Critical Care Medicine 189: 779–786.
18. Lee, W., S.K. Ku, D. Lee, T. Lee, and J.S. Bae. 2014. Emodin-6-O-beta-D–glucoside inhibits high-glucose-induced vascular inflammation. Inflammation 37: 306–313.
19. Mackman, N., K. Brand, and T.S. Edgington. 1991. Lipopolysaccharide-mediated transcriptional activation of the human tissue factor gene in THP-1 monocytic cells requires both activator protein 1 and nuclear factor kappa B binding sites. Journal of Experimental Medicine 174: 1517–1526.
20. Fuseler, J.W., D.M. Merrill, J.A. Rogers, M.B. Grisham, and R.E. Wolf. 2006. Analysis and quantitation of NF-kappaB nuclear translocation in tumor necrosis factor alpha (TNF-alpha) activated vascular endothelial cells. Microscopy and Microanalysis 12: 269–276.
21. Lee, W., S.K. Ku, and J.S. Bae. 2014. Vascular barrier protective effects of orientin and isoorientin in LPS-induced inflammation in vitro and in vivo. Vascular Pharmacology 62: 3–14.
22. Joubert, E., W.C. Gelderblom, A. Louw, and D. de Beer. 2008. South African herbal teas: aspalathus linearis, Cyclopia spp. and Athrixia phylicoides—a review. Journal of Ethnopharmacology 119: 376–412.
23. Ku, S.K., S. Kwak, and J.S. Bae. 2014. Orientin inhibits high glucose-induced vascular inflammation in vitro and in vivo. Inflammation. (in press).
24. Kim, J.A., J.A. Berliner, R.D. Natarajan, and J.L. Nadler. 1994. Evidence that glucose increases monocyte binding to human aortic endothelial cells. Diabetes 43: 1103–1107.
25. Lee, Y.J., D.G. Kang, J.S. Kim, and H.S. Lee. 2008. Lycopus lucidus inhibits high glucose-induced vascular inflammation in human umbilical vein endothelial cells. Vascular Pharmacology 48: 38–46.
26. Takaishi, H., T. Taniguchi, A. Takahashi, Y. Ishikawa, and M. Yokoyama. 2003. High glucose accelerates MCP-1 production via p38 MAPK in vascular endothelial cells. Biochemical and Biophysical Research Communications 305: 122–128.
27. Morigi, M., S. Angioletti, B. Imberti, et al. 1998. Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion. Journal of Clinical Investigation 101: 1905–1915.
28. Kashiwagi, A., T. Asahina, Y. Nishio, et al. 1996. Glycation, oxidative stress, and scavenger activity: glucose metabolism and radical scavenger dysfunction in endothelial cells. Diabetes 45(Suppl 3): S84–S86.
29. Du, X., K. Stocklauser-Farber, and P. Rosen. 1999. Generation of reactive oxygen intermediates, activation of NF-kappaB, and induction of apoptosis in human endothelial cells by glucose: role of nitric oxide synthase? Free Radical Biology and Medicine 27: 752–763.
30. Laakso, M. 1999. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48: 937–942.
31. Kannel, W.B., and D.L. McGee. 1979. Diabetes and cardiovascular disease. The Framingham study. JAMA 241: 2035–2038.
32. Nannipieri, M., L. Rizzo, A. Rapuano, A. Pilo, G. Penno, and R. Navalesi. 1995. Increased transcapillary escape rate of albumin in microalbuminuric type II diabetic patients. Diabetes Care 18: 1–9.
33. Wardle, E.N. 1994. Vascular permeability in diabetics and implications for therapy. Diabetes Research and Clinical Practice 23: 135–139.
34. Tooke, J.E. 1995. Microvascular function in human diabetes. A physiological perspective. Diabetes 44: 721–726.
35. Gerrity, R.G. 1981. The role of the monocyte in atherogenesis: I. Transition of blood-borne monocytes into foam cells in fatty lesions. American Journal of Pathology 103: 181–190.
36. Esposito, C., G. Fasoli, A.R. Plati, et al. 2001. Long-term exposure to high glucose up-regulates VCAM-induced endothelial cell adhesiveness to PBMC. Kidney International 59: 1842–1849.
37. Hamuro, M., J. Polan, M. Natarajan, and S. Mohan. 2002. High glucose induced nuclear factor kappa B mediated inhibition of endothelial cell migration. Atherosclerosis 162: 277–287.
38. Lopes-Virella, M.F., and G. Virella. 1992. Immune mechanisms of atherosclerosis in diabetes mellitus. Diabetes 41(Suppl 2): 86–91.
39. Bae, J.S. 2012. Role of high mobility group box 1 in inflammatory disease: focus on sepsis. Archives of Pharmacal Research 35: 1511–1523.
40. Kado, S., T. Wakatsuki, M. Yamamoto, and N. Nagata. 2001. Expression of intercellular adhesion molecule-1 induced by high glucose concentrations in human aortic endothelial cells. Life Sciences 68: 727–737.
41. Hansson, G.K., and P. Libby. 2006. The immune response in atherosclerosis: a double-edged sword. Nature Reviews Immunology 6: 508–519.
42. Boisvert, W.A. 2004. Modulation of atherogenesis by chemokines. Trends in Cardiovascular Medicine 14: 161–165.
43. Inoguchi, T., P. Li, F. Umeda, et al. 2000. High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49: 1939–1945.
44. Dunlop, M. 2000. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney International. Supplement 77: S3–S12.
45. Han, H.J., Y.J. Lee, S.H. Park, J.H. Lee, and M. Taub. 2005. High glucose-induced oxidative stress inhibits Na+/glucose cotransporter activity in renal proximal tubule cells. American Journal of Physiology. Renal Physiology 288: F988–F996.
46. Rimbach, G., G. Valacchi, R. Canali, and F. Virgili. 2000. Macrophages stimulated with IFN-gamma activate NF-kappa B and induce MCP-1 gene expression in primary human endothelial cells. Molecular Cell Biology Research Communications 3: 238–242.
47. Uemura, S., H. Matsushita, W. Li, et al. 2001. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circulation Research 88: 1291–1298.
48. Nakamura, Y., S. Watanabe, N. Miyake, H. Kohno, and T. Osawa. 2003. Dihydrochalcones: evaluation as novel radical scavenging antioxidants. Journal of Agricultural and Food Chemistry 51: 3309–3312.
49. Rezk, B.M., G.R. Haenen, W.J. van der Vijgh, and A. Bast. 2002. The antioxidant activity of phloretin: the disclosure of a new antioxidant pharmacophore in flavonoids. Biochemical and Biophysical Research Communications 295: 9–13.
50. Krafczyk, N., F. Woyand, and M.A. Glomb. 2009. Structure-antioxidant relationship of flavonoids from fermented rooibos. Molecular Nutrition & Food Research 53: 635–642.
51. Snijman, P.W., E. Joubert, D. Ferreira, et al. 2009. Antioxidant activity of the dihydrochalcones aspalathin and nothofagin and their corresponding flavones in relation to other rooibos (Aspalathus linearis) flavonoids, epigallocatechin gallate, and trolox. Journal of Agricultural and Food Chemistry 57: 6678–6684.